Zobrazeno 1 - 10
of 519
pro vyhledávání: '"Gemcitabine and cisplatin"'
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background A combination of immune checkpoint inhibitors (ICIs) and chemotherapy has demonstrated excellent clinical efficacy and safety in treating a variety of cancers, including urothelial carcinoma (UC). However, its efficacy and safety
Externí odkaz:
https://doaj.org/article/5293d6122c6f40999693935edc380d6d
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundIntrahepatic cholangiocarcinoma (ICC) is a highly aggressive primary liver cancer, with increasing incidence worldwide. Effective first-line treatments for advanced ICC patients are currently limited. Therefore, our study aimed to assess th
Externí odkaz:
https://doaj.org/article/9d880d6d2a844c84a011cbff746de81d
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Xiang Ren, Yiqun Tian, Zhixian Wang, Jing Wang, Xing Li, Yisheng Yin, Ruibao Chen, Ying Zhan, Xiaoyong Zeng
Publikováno v:
BMC Urology, Vol 22, Iss 1, Pp 1-7 (2022)
Abstract Background Combining immune checkpoint inhibitors with chemotherapy can synergistically improve antitumor activity and are generally well tolerated. Recently, the efficacy and safety of combination therapy has been demonstrated for many canc
Externí odkaz:
https://doaj.org/article/ccfe160267404960aad845347e0fbc79
Autor:
Yusuke Wakasa, Yoshikazu Toyoki, Tomomi Kusumi, Yuma Kameyama, Tadashi Odagiri, Hiroyuki Jin, Makoto Nakai, Kazunori Aoki, Hiroaki Kawashima, Masaaki Endo
Publikováno v:
Surgical Case Reports, Vol 8, Iss 1, Pp 1-6 (2022)
Abstract Background Conversion surgery, which is defined as chemotherapy or chemoradiotherapy followed by radical surgery, may improve survival of patients with initially unresectable advanced biliary tract cancer, including gallbladder cancer. Howev
Externí odkaz:
https://doaj.org/article/4f252dbda58847ef9730c0233374ce9d
Autor:
Yuya Miura, Ryo Ashida, Teiichi Sugiura, Katsuhisa Ohgi, Mihoko Yamada, Shimpei Otsuka, Akiko Todaka, Katsuhiko Uesaka
Publikováno v:
Surgical Case Reports, Vol 8, Iss 1, Pp 1-9 (2022)
Abstract Background Conversion surgery for initially unresectable gallbladder cancer is rarely performed due to the low response rate for systemic chemotherapy, and a pathological complete response is seldom achieved. Case presentation A 67-year-old
Externí odkaz:
https://doaj.org/article/207edcfec739431d85999f69924eeb0b
Autor:
Sunisa Prasopporn, Orawan Suppramote, Ben Ponvilawan, Chanette Jamyuang, Jantappapa Chanthercrob, Amphun Chaiboonchoe, Pimkanya More-Krong, Kamonchanok Kongsri, Monthira Suntiparpluacha, Rawisak Chanwat, Krittiya Korphaisarn, Seiji Okada, Somponnat Sampattavanich, Siwanon Jirawatnotai
Publikováno v:
Frontiers in Oncology, Vol 12 (2023)
Externí odkaz:
https://doaj.org/article/ec0a8457396d49cb9b31dd5bb0eb9d12
Autor:
Sunisa Prasopporn, Orawan Suppramote, Ben Ponvilawan, Chanette Jamyuang, Jantappapa Chanthercrob, Amphun Chaiboonchoe, Pimkanya More-Krong, Kamonchanok Kongsri, Monthira Suntiparpluacha, Rawisak Chanwat, Krittiya Korphaisarn, Seiji Okada, Somponnat Sampattavanich, Siwanon Jirawatnotai
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Cholangiocarcinoma (CCA) is a highly lethal gastrointestinal malignancy that has one of the worst prognoses among solid tumors. The combination of Gemcitabine + Cisplatin (GEM/CIS) remains the standard first-line treatment for advanced stage CCA. How
Externí odkaz:
https://doaj.org/article/911c30605c684512880a37fea8fa7666
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Introduction: In 2021, two phase III clinical trials confirmed that toripalimab or camrelizumab combined with gemcitabine and cisplatin (TGP or CGP) provide more benefits in the first-line treatment of R/M NPC than GP. Fortunately, TGP and CGP were r
Externí odkaz:
https://doaj.org/article/c4a904a2db9f41069eb68d0e26171338
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundNeoadjuvant chemotherapy has been accepted as an effective curative treatment for muscle-invasive bladder cancer patients and has resulted in better survival outcomes than radical cystectomy or a cisplatin-based regimen. In the present stud
Externí odkaz:
https://doaj.org/article/9a5fcc5c565f4660bd58ef84a6227cd0